Rick Simpson Oil in Weakley County: The Complete Guide by OilWell Cannabis

Weakley County, nestled in the heart of Northwest Tennessee, is a place where tradition runs deep and community values matter. From the rolling farmlands of Dresden to the historic streets of Martin, our county is known for its hardworking people, strong agricultural roots, and close-knit families. But like many rural communities across America, Weakley County faces its share of health challenges—chronic pain, cancer diagnoses, sleep disorders, and the lingering effects of stress and trauma.

For years, residents of Weakley County have searched for natural, effective ways to manage these conditions. Many have heard about Rick Simpson Oil (RSO), the powerful cannabis extract that gained fame for its potential therapeutic benefits. But with so much conflicting information online, it can be hard to know what’s real, what’s safe, and what’s right for you or your loved ones.

That’s why we’re here.

At OilWell Cannabis, we believe in honest education, science-backed formulations, and products that respect both tradition and innovation. Our Rick Simpson Oil formulas are designed to bring the healing potential of cannabis to Weakley County in a way that’s legal, safe, and tailored to your needs. Whether you’re dealing with chronic pain, recovering from chemotherapy, struggling with insomnia, or simply looking for a natural way to support your well-being, we’ve created this guide to help you understand RSO—what it is, how it works, and why our approach is different.

This isn’t just another product page. It’s a complete, research-backed resource for Weakley County residents who deserve the best possible information before making decisions about their health. We’ll walk you through the history of RSO, the science behind our formulas, and how our products can fit into your life—all while respecting the values and concerns of our community.

So, let’s get started.

The Story of Rick Simpson Oil: From Nova Scotia to Weakley County

Who Was Rick Simpson?

Rick Simpson wasn’t a doctor, a scientist, or a medical professional. He was a power engineer from Amherst, Nova Scotia, who stumbled into the world of cannabis advocacy after a personal crisis. In 1997, Simpson suffered a serious head injury while working at a hospital in Moncton, New Brunswick. The accident left him with persistent tinnitus, dizziness, and a host of post-concussion symptoms that conventional medicine couldn’t resolve. The medications he was prescribed either didn’t help or made things worse, and when he asked his doctor about cannabis as an alternative, the request was refused.

Simpson’s interest in cannabis deepened when he learned about a 1974 study funded by the National Institutes of Health (NIH) and conducted at the Medical College of Virginia. The study found that THC, the psychoactive compound in cannabis, slowed or shrank tumors in mice. Though the study was never replicated in controlled human trials, it became a foundational reference point for Simpson’s later work.

The turning point came in 2003, when Simpson noticed three bumps on his arm. His doctor diagnosed them as basal cell carcinoma, a form of skin cancer. Instead of pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. While there was no independent medical verification or biopsy confirmation of this outcome, the experience became the origin story of Rick Simpson Oil (RSO) and the foundation of a global movement.

The Birth of a Movement

After his 2003 experience, Simpson committed himself to producing and distributing concentrated cannabis oil. He began making large quantities of the oil and giving it away for free to cancer patients and others in his community. He charged nothing, believing that cannabis oil should be accessible to anyone who needed it. Over time, he claimed to help dozens of people with conditions ranging from cancer and chronic pain to diabetes, glaucoma, and insomnia.

Simpson’s story reached a global audience in 2005 with the release of Run From The Cure, a documentary directed by Christian Laurette. The film documented Simpson’s claims, featured testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. For many people, Run From The Cure was their first introduction to the concept of concentrated cannabis oil as medicine.

The Legal Battle

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing his plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he was raided again in 2009. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe, where he continued his advocacy from abroad.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, a book detailing his personal experience, his oil-making process, and his broader philosophical views on cannabis, medicine, and institutional suppression. He also maintained phoenixtears.ca as his primary online platform for information and advocacy.

The Legacy of Rick Simpson

Simpson’s legacy is complex. On one hand, he drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing the conversation. His advocacy helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. The term “RSO” remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary.

On the other hand, Simpson’s claims about RSO’s ability to cure cancer and other diseases were not supported by robust clinical evidence. Encouraging patients—particularly those with cancer—to rely on RSO as a primary treatment in place of proven therapies like surgery, radiation, or chemotherapy carries real risks. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative medicine literature, and Simpson’s uncompromising stance on cannabis oil as a cure-all often exceeded what the evidence could support.

Why This Matters for Weakley County

In Weakley County, where access to specialized medical care can sometimes be limited, it’s understandable that people turn to alternative treatments like RSO when conventional medicine falls short. Many of our neighbors have faced the same frustrations as Simpson—ineffective prescriptions, dismissive doctors, and a medical system that doesn’t always have the answers. But it’s also important to approach RSO with clear eyes. The oil that Simpson made was crude, unstandardized, and produced using solvents like naphtha or isopropyl alcohol, which carry significant safety risks.

At OilWell Cannabis, we honor Simpson’s legacy by building on it—not by replicating his methods, but by evolving them. Our RSO formulas are designed to address the limitations of traditional RSO while preserving its core promise: a powerful, full-spectrum cannabis extract that can support health and well-being. We’ll dive deeper into how our approach differs from Simpson’s later in this guide, but first, let’s take a closer look at the traditional RSO protocol and why it’s important to understand its risks and limitations.

The Traditional RSO Protocol: What It Was and Why It Matters

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions. Below is a detailed breakdown of the protocol as Simpson described it, along with important context for evaluating its safety and efficacy.

The 60-Gram, 90-Day Regimen

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration Schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day (morning, afternoon, and before bed). Total daily intake during this phase: approximately 30 to 45 milligrams. Simpson emphasized that the initial doses should be very small to allow the body to begin adjusting to the psychoactive effects of THC.
• Weeks 2 through 5: Double the dose approximately every four days. The purpose of the slow ramp-up was to build THC tolerance gradually and minimize disruption from the psychoactive effects. By the end of this escalation period—roughly four to five weeks in—the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.
• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed. At this dosing level, the remaining 50-plus grams of oil would be consumed over the final seven to eight weeks.

Administration Methods

• Primary method—oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it. He considered oral ingestion the most important route for systemic absorption and the primary method for internal cancers and other systemic conditions.
• Secondary method—topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days. He combined topical application with oral dosing for skin cancers.
• Not recommended as primary—inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method. He acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for the sustained, high-dose exposure he considered therapeutically essential.

Tolerance and the Psychoactive Effects

• Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks of consistent dosing at escalating levels.
• He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the “high” discourage them from continuing the protocol.
• He recommended that patients take their initial doses at night or before bed to sleep through the most intense psychoactive effects during the early titration phase.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period and that they inform family members about what to expect.

Post-Protocol Maintenance

• After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.
• He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.
• Simpson indicated that maintenance dosing was much lower than the treatment dose and that patients who had completed the full protocol would have sufficient THC tolerance to handle it comfortably.

Dietary and Lifestyle Recommendations

• Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition.
• He was not specific or systematic about dietary protocols compared to his highly detailed oil protocol—dietary advice was secondary and general.

Important Context for Evaluating This Protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

1. No controlled trial validation: There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or any other condition.

2. Assumes crude, unstandardized material: The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on the starting plant material and extraction technique.

3. Very high THC exposure: At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.

4. Real risks at these doses: Consuming 600 to 900 milligrams of THC daily carries serious risks, including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the scientific literature.

5. Oncology context: Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself.

Why This Matters for Weakley County Residents

In Weakley County, where many of us have faced serious health challenges, the idea of a natural, accessible treatment like RSO can be incredibly appealing. But it’s important to understand that Simpson’s protocol was designed for a very different product than what’s available today. Traditional RSO was crude, variable, and produced using methods that would never meet modern safety standards.

At OilWell Cannabis, we’ve taken the core idea behind RSO—a full-spectrum cannabis extract with therapeutic potential—and evolved it into something safer, more precise, and more accessible. Our RSO formulas are standardized, lab-tested, and designed to minimize the risks associated with traditional RSO while maximizing its benefits. We’ll explore those differences in detail later in this guide.

What Was Traditional Rick Simpson Oil?

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials. Below is a detailed breakdown of what traditional RSO was as a product.

Source Material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment, believing that indica strains produced better therapeutic outcomes. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization—the starting material varied by availability and growing season.

Extraction Solvent

Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. He explicitly warned against using other solvents, including butane or acetone, due to safety and purity concerns. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which is a significant safety issue.

Extraction Process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. The material was covered with solvent and agitated or stirred for several minutes to dissolve cannabinoids and other fat-soluble compounds from the plant.
3. The solvent was poured off through a filter, typically cheesecloth or a similar mesh material, into a separate collection vessel.
4. The process was repeated a second time with fresh solvent on the same plant material to extract remaining cannabinoids.
5. The combined solvent washes—now a dark, cannabinoid-rich liquid—were placed in a rice cooker or similar open-vessel heating device.
6. The solvent was evaporated at relatively low heat. Simpson recommended a rice cooker specifically because it maintains a temperature range that evaporates the solvent without exceeding the point at which cannabinoids degrade significantly. However, this temperature was still high enough to decarboxylate THCa into THC and to destroy most volatile terpenes.
7. As the solvent evaporated, a thick, dark oil remained at the bottom of the vessel.
8. The final oil was transferred into oral syringes for storage and dosing.

Appearance and Physical Characteristics

Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid Profile

• Primarily decarboxylated delta-9 THC: The heat involved in solvent evaporation converted essentially all THCa in the extract into delta-9 THC. Traditional RSO was therefore an activated, THC-dominant product.
• Naturally occurring minor cannabinoids: Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.
• No ratio control: There was no ability to adjust or standardize specific cannabinoid ratios. The profile was entirely determined by the genetics and growing conditions of the source plant.
• Estimated THC content: Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight, though this was never lab-verified in the traditional production context.

Terpene Content

Minimal to none. The combination of solvent extraction (which dissolves terpenes into the solvent along with cannabinoids) and the subsequent high-heat evaporation process (which volatilizes terpenes at temperatures well below cannabinoid degradation thresholds) meant that traditional RSO was effectively stripped of its terpene content. This is a significant distinction from modern formulations that deliberately preserve or reintroduce terpenes.

Standardization and Testing

None. Every batch of traditional RSO was different because it depended entirely on the starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. Simpson operated before cannabis legalization and the standardized lab-testing infrastructure that came with it. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual Solvent Risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha in particular is a complex mixture of petroleum hydrocarbons that may contain benzene, toluene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging—which is difficult to verify without lab testing—leaves potentially harmful residues in the finished oil. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to address this problem.

Why This Matters for Weakley County

For residents of Weakley County, understanding what traditional RSO was helps you make informed decisions about the products available today. Many products labeled as “RSO” in dispensaries or online bear little resemblance to what Simpson originally made. Some may be safer and more standardized, while others may still carry the same risks as traditional RSO.

At OilWell Cannabis, we’ve addressed these risks by creating a solvent-free, lab-tested, multi-cannabinoid formula that preserves the therapeutic potential of RSO while eliminating the dangers associated with traditional production methods. We’ll explore our approach in detail later in this guide.

Simpson’s Claims vs. the Evidence: What the Science Actually Says

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer—including terminal cases—and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career.

But how do these claims hold up against the actual evidence? Let’s evaluate them using the same standards applied throughout this document.

What Simpson Was Not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally—with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the Preclinical Literature Shows

The preclinical cannabinoid-cancer literature does exist, and it is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines.
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids.
• These findings have generated legitimate scientific interest and ongoing research.

However, it’s important to note that these findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast, well-documented across all of oncology research, and especially relevant here.

What the Preclinical Literature Does Not Show

• These findings have not translated into proven human cancer cures. No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced the kind of results that would support cancer-cure claims.

Institutional Positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment.
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting.
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• The National Center for Complementary and Integrative Health (NCCIH) explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cure.

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy—however scientifically imprecise—helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term “RSO” itself remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary.

What He Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative medicine literature.

Why This Matters for Weakley County

In Weakley County, where many of us have faced cancer diagnoses—either personally or in our families—it’s natural to seek out alternative treatments when conventional medicine feels overwhelming or ineffective. But it’s also important to approach those treatments with a clear understanding of what the science actually says.

At OilWell Cannabis, we believe in the therapeutic potential of cannabinoids, but we also believe in honesty. Our RSO formulas are designed to complement—not replace—conventional medical care. They are backed by research, standardized for safety, and formulated to minimize risks while maximizing benefits. Later in this guide, we’ll explore how our approach differs from Simpson’s and how our products can fit into a holistic health plan.

The Evolution of RSO: From Tradition to Innovation

The term “RSO” has become generic in the cannabis industry. Many products labeled as RSO today bear little resemblance to what Simpson originally made. In dispensaries, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use.

Simpson himself was critical of commercial products that used the RSO name while departing significantly from his original method and philosophy. He maintained that many products sold as RSO did not meet his standards and that the commercialization of cannabis oil contradicted his original intent. Simpson’s model was explicitly anti-commercial—he gave the oil away for free and urged others to make their own rather than buy from companies.

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model in which anyone could grow cannabis, extract the oil, and treat themselves or their loved ones without corporate or governmental intermediaries. The modern cannabis industry has done something very different: it has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas in this document.

Traditional RSO vs. Modern Formulated RSO

The following table summarizes the key differences between traditional RSO as Simpson defined it and the modern formulated approach used in OilWell’s products.

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content (553 mg/mL)
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as a separate ingredient at 1,500 mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Why OilWell’s Formulas Diverge from Traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways:

1. Multi-cannabinoid approach: Traditional RSO relied on whatever single strain the maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited.

2. Terpene preservation and addition: Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5 percent with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing.

3. THCa as a separate ingredient: Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500 mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC.

4. Reduced delta-9 THC dominance: Traditional RSO was overwhelmingly delta-9 THC—often 60 to 90 percent of total cannabinoid content. OilWell’s sublingual formula uses delta-9 THC at only 90 mg while incorporating delta-8 THC at 6,000 mg and distributing the remaining cannabinoid content across CBD (4,500 mg), CBG (3,000 mg), CBN (750 mg), and CBC (750 mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

5. Product format innovation: Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30 mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation, acknowledging that different delivery routes have different pharmacokinetic profiles.

Solvent Safety and Extraction Evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other compounds with established toxicity. Isopropyl alcohol, while cleaner than naphtha, is also not intended for internal consumption. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

The Decarboxylation Question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker—typically sustained at or near the boiling point of the solvent, which for naphtha is roughly 60 to 80 degrees Celsius and for isopropyl alcohol roughly 82 degrees Celsius—was sufficient to convert essentially all THCa in the extract into delta-9 THC. This conversion is thermodynamically favored and proceeds readily at these temperatures over the durations involved in solvent evaporation.

As a result, the acidic cannabinoids that exist abundantly in raw cannabis plant material—including THCa, CBDa, CBGa, and others—were lost as distinct compounds in traditional RSO. The finished oil was a decarboxylated, activated product dominated by neutral (non-acidic) cannabinoids.

OilWell’s sublingual formula deliberately preserves THCa at 1,500 mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile, which notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage—because THCa can convert to THC under heating or over time.

Terpene Loss in Traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157 degrees Celsius, with many of the most abundant terpenes—including myrcene, limonene, and pinene—having boiling points below 180 degrees Celsius. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash along with cannabinoids; and second, by evaporating them off during the high-heat solvent-removal phase.

This meant that traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5 percent with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each of these terpenes has its own evidence profile, and the entourage-effect literature provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

Evidence Standards Then and Now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense.

At OilWell Cannabis, we take a fundamentally different approach. Our GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science. Where Simpson relied on personal testimony, we rely on published literature and institutional sources.

Simpson’s Protocol vs. Modern Dosing Considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward—the products are fundamentally different.

Several key differences illustrate why:

• Cannabinoid concentration: OilWell’s sublingual formula delivers 553 mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios: Simpson’s oil was approximately 60 to 90 percent delta-9 THC. OilWell’s formula distributes 16,590 mg of total cannabinoids across CBD (4,500 mg), CBG (3,000 mg), delta-8 THC (6,000 mg), THCa (1,500 mg), delta-9 THC (90 mg), CBN (750 mg), and CBC (750 mg)—a completely different pharmacologic profile.
• Terpene presence: Simpson’s oil had no terpenes. OilWell’s formula includes live terpenes at 5 percent, which may influence absorption, effect, and tolerability.
• Delta-9 THC exposure: Simpson’s protocol at peak dosing delivered approximately 600 to 900 mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90 mg of delta-9 THC in the entire 30 mL bottle (3 mg per mL), making the per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by the per-compound evidence in the GENERAL KNOWLEDGE section and by responsible titration principles that account for the safety profile of each individual cannabinoid.

Introducing OilWell Cannabis: A New Approach to RSO for Weakley County

The Origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin’s story is one of resilience, innovation, and a deep commitment to helping others. He grew up in McAllen, Texas, just across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts—vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities outside of retail and healthcare. Reynosa, on the other hand, is an industrial hub plagued by violence and cartel activity, making it a harsh environment for anyone growing up there.

Colin’s childhood in McAllen was marked by exposure to both the opportunities and the challenges of life along the border. He learned to hustle early on, taking on risky work transporting items across the border. Those experiences exposed him to the complexities and dangers of life in that region. Many of his best friends have been killed or are in prison because of the associated dangers. By the age of sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths available to him. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative to harder substances. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—would eventually define OilWell’s approach.

The Story of Bentley: Where It All Began

The company’s origin story begins with a dog named Bentley. Bentley wasn’t just a pet—he was family, a companion who stood by Colin through some of the toughest times in his life. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs, and the pain medications prescribed by the vet were expected to destroy his internal organs, causing more pain and suffering. The choice was between a painful, prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss and seen too much suffering in his life. Bentley was a fighter, just like him, and Colin wasn’t ready to let him go. In a desperate search for alternatives, he stumbled upon the healing properties of CBD—through a question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience, but it was recreational. Getting high. He had never explored the therapeutic and medicinal applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It wasn’t a cure, but it was a lifeline. And that lifeline delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was nothing short of a miracle. From paralyzed and facing euthanasia to fetching his ball—this wasn’t a placebo effect. Dogs don’t respond to placebo. This was cannabinoid medicine doing what pharmaceuticals couldn’t.

Bentley lived another ten years, passing naturally at the age of twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. CBD alone couldn’t address neurodegeneration, dementia, glaucoma, and arthritis simultaneously. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered—Bentley’s life depended on formula accuracy, not guesswork.

Bentley’s journey was Colin’s entry into the world of cannabis beyond just getting high. It became a mission to create real solutions that help alleviate pain and suffering, not just for pets but for people as well. Bentley’s story is the foundation of OilWell Cannabis, driving its commitment to quality, innovation, and compassionate care.

Colin’s Personal Journey: From PTSD to Peace

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction, a battle that many veterans and trauma survivors in Weakley County can relate to. When he decided to break free from Xanax, he did it cold turkey—a feat that is notoriously difficult and dangerous—using the cannabinoid knowledge he had developed keeping Bentley alive.

The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD. This isn’t theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, and the discovery that cannabinoids work when pills don’t.

A Company Built on Trust and Transparency

Over time, the therapeutic benefits of cannabis that Colin first discovered through his efforts to save Bentley became the core of his work. He has developed formulas that doctors use for conditions like Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. His focus has always been on making cannabis accessible and effective for everyone, including vegans, diabetics, and those with specific health needs.

ABC13 KTRK Houston—Houston’s number-one news source—featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023. These segments covered Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

Colin’s quote from the first ABC13 feature in September 2019 captures the OilWell philosophy: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Today, OilWell Cannabis operates from Montrose, Houston, Texas (810 Richmond Avenue, Houston, TX 77006). The company has been operating since 2019, generates approximately one million dollars in annual revenue, maintains a near-5.0 Google rating, and is Texas DSHS licensed. OilWell’s products are not mass-produced—they are carefully crafted with a personal touch, from the artwork on the packaging to the formulations inside. All artwork, formulations, and packaging are created in-house in Houston, using only OilWell’s own recipes and ideas.

The OilWell RSO Philosophy: Four Core Principles

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define OilWell’s approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping: No medical card is required. Anyone age twenty-one or older can purchase. OilWell ships nationwide across the United States and internationally to customers who verify local legality. Simpson believed medicine should be accessible to everyone; OilWell built a product and distribution model that makes that accessible legally.

2. Patient-controlled potency: THCa is sold in its acidic, non-psychoactive form. The customer decides whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; OilWell engineered a product that puts that control in the customer’s hands through chemistry rather than rhetoric.

3. Open-source formulas: OilWell publishes their complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; OilWell adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe.

4. Evidence-informed, not evidence-overstating: The GENERAL KNOWLEDGE section in this document represents OilWell’s commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; OilWell has that access and uses it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill Compliance and the THCa Legal Framework

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level in the United States. This legal framework is the foundation of OilWell’s RSO product design.

OilWell’s RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in most states.

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance of this framework is substantial. The customer can decarboxylate THCa into delta-9 THC at home by heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC in the formula, this produces approximately 1,405 milligrams of total delta-9 THC—giving the product psychoactive potency comparable to traditional illegal RSO, entirely at the customer’s discretion after purchase.

This means the same product can function as a non-psychoactive anti-inflammatory (used raw) or as a full-potency psychoactive cannabinoid product (after home decarboxylation). The customer controls the decision. The product is legal everywhere all component cannabinoids are legal, which enables international shipping to jurisdictions where hemp-derived products with less than 0.3 percent delta-9 THC are permitted.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with their local laws regarding cannabinoid products. OilWell ships with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

Open-Source Formulas: Why OilWell Publishes Everything

OilWell publishes their complete RSO formulas—every cannabinoid, every milligram amount, every percentage—in public documents including this one. The RSO Sublingual Oil formula and RSO Vape Cartridge formula are detailed in full later in this guide.

The rationale is straightforward: if someone cannot afford OilWell’s products—$129.99 for the sublingual oil, $49.99 for the vape cartridge—they can see exactly what the formula contains, source the individual cannabinoid distillates and isolates, and make their own version. The formulas in the RSO Sublingual Oil and RSO Vape Cartridge sections of this guide are the open-source formulas.

This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. He never patented his method. He never charged patients. OilWell adapted that ethos for the modern cannabinoid marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

As Colin Valencia said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy didn’t start with RSO—it started with Bentley. On the About Us page, Colin published the actual CBD golden paste recipe that saved Bentley’s life, so that any pet owner facing a similar crisis could make it themselves:

CBD Golden Paste Recipe for Pets—The Original Open-Source Formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water: In a saucepan, combine the turmeric powder and water, stirring over low heat. Stir continuously until it forms a thick paste. This should take about 7 to 10 minutes. Add a little more water if it becomes too thick.
2. Add the coconut oil and pepper: Once you have a thick paste, add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Cool and store: Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Dosage: Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start with a low dose and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult with a veterinarian before starting any new supplement regimen for a pet.

This recipe—published for free, years before the RSO formulas were open-sourced—demonstrates that the pattern is consistent. Colin gave away the formula that saved Bentley before he gave away the formula designed for people. The open-source ethos is not a marketing strategy. It is the foundational behavior of the company.

The Decarboxylation Choice: Patient-Controlled Potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity—the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options for the customer:

Option 1—Raw, no heat: All 1,500 milligrams stays as THCa—completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

Option 2—Fully activated, home decarboxylation: Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC already in the formula, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO—100 percent legally, because decarboxylation occurs at the customer’s discretion after purchase. The customer may also transfer a controlled portion of the oil from the original bottle into a second empty oven-safe glass container, decarboxylating only what they intend to use and preserving the remainder in its raw THCa form.

Option 3—Vape, auto-decarboxylation: The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

The conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in the customer’s hands—aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach.

Solvent-Free Production

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production, as discussed earlier in this guide.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile—a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through the OilWell website.

The Broader OilWell Product Portfolio

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach—OilWell’s most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive.

Peace Gummies—Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief—Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis.

Custom creations—OilWell offers custom-made products tailored to the specific needs of individual customers. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, OilWell designs targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Two Product Formats: Sublingual Oil and Vape Cartridge

OilWell offers the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil – $129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption through oral mucosa)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent (sublingual route partially bypasses first-pass liver metabolism)
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge – $49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent (variable, dependent on inhalation technique)
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

Complete RSO Guide—OilWell’s full product guide with science, competitive analysis, protocols, and ordering information.

When to Use Each Format

Use Case	Recommended Format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive Comparison: OilWell RSO vs. Alternatives

The following tables present factual comparisons between OilWell’s RSO formula and other RSO products available on the market. These comparisons are based on publicly available product specifications and are presented for informational context.

OilWell RSO vs. Texas TCUP Dispensary RSO (e.g., Texas Original)

Dimension	TCUP Dispensary RSO	OilWell RSO
Cannabinoid profile	THC-only (approx. 420 mg THC per 0.5 g syringe)	7 cannabinoids: CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, CBC
CBG content	0 mg	3,000 mg
CBN content	0 mg	750 mg
CBC content	0 mg	750 mg
Patient-controlled potency	No—always fully psychoactive	Yes—THCa non-psychoactive until heated by customer
Access requirements	TCUP medical card with qualifying condition	Age 21+ only, no medical card required
Qualifying conditions	Cancer, PTSD, epilepsy, autism, terminal illness, ALS, MS, seizure disorders, incurable neurodegenerative diseases	None required
Delivery	Must travel to physical dispensary location	Same-day delivery Houston, nationwide and international shipping
Farm Bill compliant	No—state medical cannabis program	Yes—less than 0.3% delta-9 THC

OilWell RSO vs. Hemp CBD RSO (e.g., Lazarus Naturals)

Dimension	Lazarus Naturals RSO (10 mL, 1,000 mg)	OilWell RSO (30 mL, 16,590 mg)
Total cannabinoids	1,000 mg	16,590 mg
CBD content	Approximately 950 mg	4,500 mg
CBG content	15.5 mg	3,000 mg
CBN content	0.7 mg	750 mg
Delta-8 THC	0 mg	6,000 mg
THCa (convertible to delta-9 THC)	Minimal	1,500 mg (converts to approximately 1,315 mg delta-9 THC)
Psychoactive option	No meaningful psychoactive effect	Yes—via THCa decarboxylation and delta-8 THC
Approximate price	$40 to $50	$129.99

OilWell RSO vs. Traditional Illegal RSO

This comparison is presented in the Traditional RSO vs. modern formulated RSO table earlier in this guide. Refer to that table for the full eleven-dimension comparison.

Condition-Specific Usage Context

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section of this document and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence, delta-9 THC nausea and vomiting evidence, CBD anxiolytic buffering

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition

Sleep Support

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—the dosage level investigated in the 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence, cannabis and sleep review literature

Anxiety and Stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence, CBG pharmacology, limonene entourage-effect evidence

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Delivery and Global Accessibility: Bringing RSO to Weakley County

OilWell operates the only same-day RSO delivery system in Houston. Beyond Houston, the company ships nationwide and internationally.

Houston Same-Day Delivery

Zone	Coverage	Delivery Fee	Typical Turnaround
Texas Medical Center	All 60+ TMC institutions (MD Anderson, Memorial Hermann, Methodist, Texas Children’s, St. Luke’s, and more)	FREE	2 to 4 hours
Inner Loop (610)	Downtown, Midtown, Montrose, Heights, Rice Village, Museum District, River Oaks, Upper Kirby, Galleria	$5	2 to 4 hours
Within Beltway 8	Bellaire, Memorial, Spring Branch, South Houston, Pasadena (partial), Hobby Airport area	$10	3 to 5 hours
Greater Houston suburbs	Katy, Sugar Land, Pearland, Clear Lake, Woodlands, Cypress, Tomball, Humble, Kingwood	$15	4 to 6 hours
Extended region (60 miles)	Galveston, Baytown, Rosenberg, Conroe, La Porte, Seabrook	$20 to $25	Same-day if ordered before 2 PM

Free delivery to the Texas Medical Center—the world’s largest medical complex with over 10 million patient visits annually—reflects OilWell’s commitment to accessibility for the patients who need it most.

Nationwide Shipping

• All 50 states where Farm Bill-compliant products are legal
• USPS Priority Mail (2 to 3 business days), FedEx and UPS Ground (3 to 5 business days)
• Discreet packaging with no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments
• Signature-required option available

International Shipping

OilWell ships internationally and has already delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3 percent delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the 2018 Farm Bill and is shippable to jurisdictions with compatible hemp laws.

• All international packages include full documentation, Certificates of Analysis (COAs), and receipts for customs purposes
• Minimum flat-fee shipping applies; excessive international shipping costs are billed to the customer
• The customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk
• Contact: (832) 416-2816 or [email protected]

The significance of international access cannot be overstated. Rick Simpson couldn’t ship his oil anywhere—it was Schedule I, illegal to produce, possess, or transport. A cancer patient in Germany, a chronic pain patient in Australia, or a veteran in the United Kingdom can now potentially access the same clinical-strength multi-cannabinoid RSO formula that a Houston resident receives via same-day delivery. OilWell built a product that can move across borders legally—completing a piece of Rick Simpson’s vision that prohibition made impossible during his lifetime of advocacy.

OilWell’s PANDEM1C SEO technology—a proprietary system with 14 million distinct geopolitical locations in its database and over 300 AI models—drives organic search visibility across six continents, making OilWell products discoverable to international patients searching for RSO in their own language.

The Science Behind OilWell’s RSO: What the Research Says

At OilWell Cannabis, we believe that education is the foundation of informed decision-making. That’s why we’ve created this comprehensive guide—not just to introduce our products, but to help Weakley County residents understand the science behind them. Below, we’ll explore the evidence profiles for each cannabinoid and terpene in our RSO formulas, as well as the broader research landscape that informs our approach.

Research Method and Evidence Weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters because the evidence base is not evenly distributed. Of the compounds listed in this document, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature.

Institutional Baseline from NIH and Related Sources

• The National Center for Complementary and Integrative Health (NCCIH) states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It also notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research.
• NCCIH also emphasizes that the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals.
• Safety concerns repeatedly highlighted by NIH and institutional sources include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns.
• NCCIH specifically warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions.

Cannabinoids: Evidence Profiles

CBD (Cannabidiol)

• Evidence profile: Strongest human evidence in the current formula set, especially when CBD is studied as a purified product rather than as a loose wellness ingredient.
• What is best supported: Purified CBD has the most credible human evidence in seizure disorders, and this is the clearest major-example indication acknowledged by institutional and peer-reviewed literature.
• Anxiety research: A 2024 systematic review and meta-analysis covering 316 participants across eight eligible articles reported a statistically significant anxiolytic signal, but the authors also stressed that the clinical sample remains limited and that more trials are needed before broad conclusions are justified.
• Pain research: A 2024 systematic review of clinical and preclinical CBD monotherapy studies concluded that the pain literature is promising but heterogeneous, with trial quality and consistency still limiting confidence in broad analgesic claims.
• Sleep research: A 2023 insomnia review found that the literature remains methodologically weak, with many studies relying on nonvalidated subjective measures and relatively few objective sleep assessments.
• Safety and interaction concerns: A 2023 systematic review and meta-analysis found a real signal for liver enzyme elevation and possible drug-induced liver injury in some CBD contexts, which is especially relevant for concentrated oral products and polypharmacy settings. NCCIH separately flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions as important considerations.
• Bottom line: CBD is the most evidence-developed nonintoxicating cannabinoid in this file, but even here, strong evidence is concentrated in a few specific indications rather than in the broad, generalized wellness claims often seen in marketing.

CBG (Cannabigerol)

• Evidence profile: Mostly review-level and preclinical; human evidence remains sparse.
• Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling, which makes it mechanistically interesting but not yet clinically established.
• Potential research areas: Published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature human therapeutic conclusions.
• Caution: One of the key points from the 2021 pharmacology review is that CBG is already being sold commercially while the evidence base remains thin, which means claims frequently outrun the science.
• Bottom line: CBG is a serious research topic, but at present it should be described as a promising minor cannabinoid with limited clinical validation rather than as a proven therapeutic cannabinoid.

Delta-8 THC

• Evidence profile: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC.
• Comparative pharmacology: A 2022 review concluded that delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity in animals and humans, but it appears less potent than delta-9 THC, likely in part because of weaker CB1 affinity.
• Public-health literature: A 2023 scoping review found that much of the delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. The same review also noted reports of adverse consequences and emphasized regulatory and product-quality concerns.
• Manufacturing context: The recent chemistry and pharmacology review reinforces that commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter.
• Bottom line: Delta-8 THC should be treated as a psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and more manufacturing-quality uncertainty than many consumers realize.

THCa (Tetrahydrocannabinolic Acid)

• Evidence profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence.
• What it is: THCa is the acidic precursor of THC and may represent a very large share of the THC-related content in raw plant material. The key formulation issue is that THCa decarboxylates into THC during heating and can also change over time during storage and processing.
• Psychoactivity: The major review source stresses that THCa itself does not produce the psychoactive effects associated with THC in humans, but the distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated.
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes.
• Bottom line: THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on route, temperature, processing, and storage. Any claim about THCa needs to account for possible conversion into THC.

Delta-9 THC

• Evidence profile: Strongest human evidence of the psychoactive cannabinoids listed here, but also the clearest adverse-effect burden.
• What is institutionally best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes, while still stressing that many other uses remain uncertain or early-stage.
• Pain evidence: A 2022 systematic review of cannabis-based products for chronic pain found that products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events.
• Pharmacokinetics and onset: Classic pharmacokinetic review literature remains useful here: inhaled THC usually produces effects within seconds to minutes, peaks roughly within 15 to 30 minutes, and tapers over a few hours; oral THC has later onset, later peak, and longer duration, which matters for both benefit and overconsumption risk.
• Mental-health risk: A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with additional concerning signals for anxiety and depression in nontherapeutic settings.
• Broader safety: Institutional and review literature also describe anxiety or panic at high doses, tachycardia, blood-pressure changes, dependency potential, withdrawal symptoms, pregnancy concerns, accidental pediatric exposure, and vape-related lung-injury concerns in THC-containing products.
• Bottom line: Delta-9 THC has legitimate therapeutic relevance in some settings, but it also carries the clearest intoxication, psychiatric, and dose-related safety liabilities in this document.

CBN (Cannabinol)

• Evidence profile: Weak human evidence; marketing has clearly moved ahead of the data.
• What it is often marketed for: Sleep and sedation. That reputation is widespread, but the clinical support is far thinner than the market suggests.
• Best direct review for the sleep claim: The 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN.
• Broader sleep literature: The 2024 updated review on cannabis and sleep concluded that overall cannabinoid sleep research still does not match the scale of real-world use, and the need for better-designed, adequately powered trials remains substantial.
• Chemical context: Downstream cannabinoid degradation pathways matter here as well; review literature on THCa notes that THC can further degrade toward CBN under certain conditions, which helps explain why CBN is often discussed in aging or oxidized cannabis chemistry contexts.
• Bottom line: CBN is one of the clearest examples in this field where cultural reputation is stronger than the current clinical evidence base.

CBC (Cannabichromene)

• Evidence profile: Emerging, intriguing, and still overwhelmingly preclinical or review-based.
• Pharmacology and therapeutic interest: The 2024 focused review on CBC argues that it has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, and highlights antinociceptive, antibacterial, and anti-seizure areas as especially interesting research targets.
• What the older literature shows: Review literature summarizing CBC in animal and in vitro work reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these signals are not yet strong evidence for patient-facing claims.
• Safety caveat: The 2024 CBC review explicitly notes that over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety.
• Bottom line: CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research, not in the category of already-validated clinical actives.

Terpenes: Evidence Profiles

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than from controlled human studies of cannabis formulations. The 2024 entourage-effect review makes this especially important: terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited.

Limonene

• Evidence profile: Largely review and preclinical, with useful safety literature.
• Potential activity: A 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory, and other possible activities, but the overwhelming share of those claims comes from nonhuman or non-cannabis literature.
• Safety note: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens and are important in patch-testing literature.
• Bottom line: Limonene is biologically active and widely discussed, but cannabis-specific therapeutic claims should stay conservative unless they are directly supported in humans.

Myrcene

• Evidence profile: Mostly preclinical, with very limited human evidence.
• Research summary: The 2021 myrcene review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties and discusses possible mechanisms, but explicitly states that human studies are lacking.
• Interpretation caution: Myrcene is often invoked in consumer language as if it were a proven sedating terpene that explains couch-lock or sleep effects. That is a stronger claim than the human evidence currently supports.
• Bottom line: Myrcene is a plausible bioactive terpene, but compound-specific clinical claims about mood, pain, or sedation remain far ahead of definitive human proof.

Caryophyllene (β-Caryophyllene)

• Evidence profile: Among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance, but still mostly preclinical.
• Why it stands out: A 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist, which is unusual and makes it especially relevant when discussing cannabis terpenes in pharmacologic rather than purely aromatic terms.
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective, and related actions are repeatedly discussed in the review literature, but human clinical confirmation remains limited.
• Bottom line: Beta-caryophyllene is arguably the strongest candidate for a terpene with cannabinoid-system significance, but it still should not be described as clinically proven for the outcomes commonly attributed to it.

Pinene

• Evidence profile: Promising preclinical literature, weak human clinical confirmation.
• Brain-health framing: The 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify future study, but it also emphasized that evidence is mostly preclinical and that well-designed clinical trials are lacking.
• Interpretation caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC-related cognitive effects remain interesting hypotheses rather than settled clinical facts.
• Bottom line: Pinene deserves scientific attention, but strong cognition-related claims should be presented as exploratory.

Linalool

• Evidence profile: Similar to pinene: substantial preclinical interest, limited direct clinical confirmation.
• Research summary: Linalool is repeatedly discussed in relation to stress, mood, and brain-health pharmacology. The 2021 brain-health review found enough preclinical signal to justify continued investigation in neurological and psychiatric contexts, while still emphasizing the lack of robust human trials.
• Additional literature: Separate review literature discusses possible antidepressant mechanisms and neuropharmacologic relevance, but this remains a translational rather than definitive clinical story.
• Safety note: As with limonene, oxidized linalool hydroperoxides are recognized allergens in dermatitis literature.
• Bottom line: Linalool is scientifically credible as a bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises.

Humulene

• Evidence profile: Translationally interesting, but still early.
• Scoping-review findings: A 2024 scoping review analyzed 340 articles and found broad preclinical evidence for anti-inflammatory and other biologic effects, with some rodent work even suggesting cannabimimetic properties via CB1 and adenosine A2a pathways.
• Interpretation caution: Those findings are valuable for hypothesis generation, but they do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes.
• Bottom line: Humulene is one of the more interesting terpene research targets in this list, but it remains far from clinically settled.

Terpinolene

• Evidence profile: One of the least clinically characterized terpenes in this file.
• Systematic-review findings: The 2021 terpinolene review screened 2,449 records and included 57 studies, concluding that terpinolene has a range of reported biological effects but that the evidence base is still dominated by in silico, in vitro, and animal studies rather than human trials.
• Interpretation caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not as established compound-specific clinical effects.
• Bottom line: Terpinolene is biologically interesting, but among the listed terpenes it remains especially underdeveloped clinically.

Research Limits and Interpretation

• The evidence base is highly uneven. CBD and delta-9 THC can support the most detailed human-facing statements; the rest require more caution.
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable. One common error in cannabis writing is to let evidence from one category stand in for another.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means the claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, and route-dependent pharmacokinetics all materially affect interpretation in real-world products.
• For THCa in particular, chemistry is destiny: storage and heating can change the actual exposure profile by converting acidic cannabinoids into neutral cannabinoids such as THC.

Common Overstatements to Avoid

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: The specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified.

• Overstatement: Myrcene is a proven human sedative that reliably explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited.

• Overstatement: Terpenes in general have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential and worth studying, but robust clinical proof remains limited and highly compound-specific.

• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing the effective exposure.

• Overstatement: Delta-8 THC is safe because it is hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns.

Practical Takeaways for OilWell’s Formulas

• The most evidence-developed actives in these formulas are CBD and delta-9 THC.
• Delta-8 THC is not a trivial or purely mild ingredient; it is a psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing and should not be interpreted the same way in raw, gently handled, and heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared with CBD and THC.
• The listed terpenes are likely highly relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

How the OilWell Formulas Connect to the Evidence

Every cannabinoid in OilWell’s formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in this document. Every terpene in OilWell’s formula—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

The formulas published later in this document are not standalone product listings. They are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to the current evidence base. Where OilWell’s RSO guide page makes specific research claims about individual cannabinoids or terpenes, this document provides the source evaluation context—the same peer-reviewed citations, the same evidence-tier assessments, and the same cautious interpretation framework.

The GENERAL KNOWLEDGE section’s evidence hierarchy, overstatement warnings, and safety notes apply equally to OilWell’s own products. This document does not exempt OilWell from the same evidence standards applied to the broader cannabinoid field. That is intentional. Our position—as stated by Colin Valencia in 2019—is that people deserve the best possible version of the information so they can give it a fair shot and decide for themselves whether it is right or wrong for them. This document is the research foundation for that position.

OilWell’s RSO Formulas: What’s Inside and Why It Matters

At OilWell Cannabis, we believe in transparency. That’s why we publish our complete formulas—every cannabinoid, every milligram amount, every percentage—so that you can see exactly what you’re getting. Below, we’ll break down our two RSO products: the RSO Sublingual Oil and the RSO Vape Cartridge. We’ll explain what each cannabinoid and terpene does, how they work together, and why we’ve chosen these specific ratios.

RSO Sublingual Oil

Cannabinoid	Amount (mg)
CBD	4,500
CBG	3,000
Delta-8 THC	6,000
THCa	1,500
Delta-9 THC	90
CBN	750
CBC	750
Total Cannabinoids	16,590

• Live Terpenes: 5%
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg

Why These Cannabinoids?

1. CBD (4,500 mg): The most evidence-developed nonintoxicating cannabinoid in our formula. CBD is well-supported for anxiety, pain, and seizure disorders, and it also helps buffer the psychoactive effects of THC, making the overall formula more tolerable.

2. CBG (3,000 mg): A promising minor cannabinoid with potential neuroprotective, anti-inflammatory, and antibacterial properties. CBG is often called the “stem cell” of cannabinoids because it is the precursor to CBD, THC, and other cannabinoids. Its inclusion reflects our commitment to a multi-cannabinoid approach.

3. Delta-8 THC (6,000 mg): A psychoactive cannabinoid that is less potent than delta-9 THC but still provides therapeutic benefits, including pain relief and nausea reduction. Delta-8 THC is also more stable and easier to synthesize than delta-9 THC, making it a practical choice for our formula.

4. THCa (1,500 mg): The acidic precursor to THC. THCa is non-psychoactive in its raw form, but it can be converted to delta-9 THC through decarboxylation (heating). This gives you control over whether you want a non-psychoactive or psychoactive experience. THCa also has potential anti-inflammatory and neuroprotective properties.

5. Delta-9 THC (90 mg): The most well-known psychoactive cannabinoid. Delta-9 THC is included at a very low dose (90 mg total in the bottle) to keep the product Farm Bill compliant (less than 0.3% delta-9 THC by dry weight). This small amount provides therapeutic benefits without overwhelming psychoactive effects, especially when combined with CBD and other cannabinoids.

6. CBN (750 mg): Often marketed for sleep, CBN is included for its potential sedative and anti-inflammatory properties. While the evidence for CBN as a sleep aid is still emerging, it is a valuable part of our multi-cannabinoid approach.

7. CBC (750 mg): A minor cannabinoid with potential anti-inflammatory, antibacterial, and neuroprotective properties. CBC is less studied than CBD or THC, but it complements the other cannabinoids in our formula.

Why These Terpenes?

Our RSO Sublingual Oil includes a 5% terpene profile with the following seven terpenes:

1. Limonene (citrus-bright): Known for its mood-enhancing and anxiolytic properties. Limonene is also a potent antioxidant and may help with digestion.

2. Myrcene: Often associated with sedative and relaxing effects. Myrcene is also a powerful anti-inflammatory and may enhance the absorption of other cannabinoids.

3. Caryophyllene (β-caryophyllene – pepper/spice): The only terpene known to act as a cannabinoid by directly activating the CB2 receptor. Caryophyllene has anti-inflammatory, analgesic, and neuroprotective properties.

4. Pinene (forest-fresh): Known for its potential cognitive-enhancing and bronchodilatory effects. Pinene may also help counteract some of the memory-impairing effects of THC.

5. Linalool (floral, lavender): Often associated with calming and sedative effects. Linalool is also a potent anti-inflammatory and may help with anxiety and depression.

6. Humulene (earthy, woody): Known for its anti-inflammatory and antibacterial properties. Humulene may also help suppress appetite, making it useful for weight management.

7. Terpinolene (piney, fruity, sparkling): Often associated with uplifting and energizing effects. Terpinolene is also a potent antioxidant and may have sedative properties at higher doses.

Why This Matters for Weakley County

In Weakley County, where many of us are dealing with chronic pain, sleep disorders, anxiety, and other health challenges, our RSO Sublingual Oil offers a powerful, multi-cannabinoid approach to wellness. The combination of CBD, CBG, delta-8 THC, THCa, and other cannabinoids provides a broad spectrum of potential benefits, while the terpenes enhance the overall experience and may contribute to the entourage effect.

The sublingual oil format is ideal for sustained relief, with an onset of 15 to 45 minutes and a duration of 4 to 6 hours. The graduated dropper allows for precise dosing in 0.1 mL increments, so you can start low and go slow to find the right dose for your needs.

RSO Vape Cartridge

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1-gram cartridge

Why This Formula?

The RSO Vape Cartridge uses the same cannabinoid and terpene profile as the sublingual oil, but in a format designed for fast relief. The vape cartridge is ideal for acute symptoms like breakthrough pain, panic attacks, or nausea, with an onset of just 1 to 2 minutes.

The vape cartridge automatically decarboxylates THCa into delta-9 THC at vaping temperatures (400 to 450°F), so every puff delivers freshly activated cannabinoids. This makes the vape cartridge a convenient option for those who want the psychoactive effects of THC without the hassle of home decarboxylation.

Why This Matters for Weakley County

For residents of Weakley County who need fast relief—whether it’s for acute pain, anxiety, or nausea—the RSO Vape Cartridge offers a discreet, portable, and effective solution. The 510-thread compatibility means it works with standard vape batteries, making it easy to use on the go.

The vape cartridge is also a great option for those who want to avoid the psychoactive effects of THC during the day but still need relief. By using the vape cartridge in small doses, you can manage symptoms without feeling overly impaired.

How to Use OilWell’s RSO: A Guide for Weakley County Residents

At OilWell Cannabis, we believe in empowering our customers with the knowledge they need to use our products safely and effectively. Below, we’ll walk you through how to use our RSO Sublingual Oil and RSO Vape Cartridge, including dosing guidelines, administration methods, and tips for getting the most out of your experience.

How to Use the RSO Sublingual Oil

Step 1: Start with a Low Dose

The key to using RSO safely and effectively is to start low and go slow. This is especially important if you’re new to cannabinoids or have a low tolerance. We recommend beginning with 0.25 to 0.5 mL of the sublingual oil and assessing the effects over 2 to 3 hours before increasing your dose.

Step 2: Administer Sublingually

To use the sublingual oil, follow these steps:

1. Shake the bottle gently to ensure the cannabinoids and terpenes are evenly distributed.
2. Use the graduated dropper to measure your desired dose (0.25 to 0.5 mL for beginners).
3. Place the oil under your tongue and hold it there for 60 to 90 seconds before swallowing. This allows the cannabinoids to absorb through the sublingual tissue, bypassing the digestive system and providing faster, more efficient relief.
4. Wait 15 to 45 minutes to feel the effects. If you don’t feel the desired relief after this time, you can take another dose, but be sure to wait at least 2 hours between doses to avoid overconsumption.

Step 3: Adjust Your Dose as Needed

Everyone’s body is different, and the right dose for you may not be the same as for someone else. Factors like body weight, metabolism, tolerance, and the severity of your symptoms can all affect how you respond to the oil. Here are some general guidelines for adjusting your dose:

• For mild symptoms (e.g., occasional anxiety, minor pain, or sleep disturbances): Start with 0.25 to 0.5 mL and increase by 0.25 mL increments as needed.
• For moderate symptoms (e.g., chronic pain, insomnia, or frequent anxiety): Start with 0.5 to 1.0 mL and adjust as needed.
• For severe symptoms (e.g., chemotherapy-related nausea, severe pain, or PTSD): Start with 1.0 to 2.0 mL and work with a healthcare provider to find the right dose for your needs.

Step 4: Decide Whether to Use the Oil Raw or Decarboxylated

One of the unique features of OilWell’s RSO Sublingual Oil is that it contains THCa, the acidic precursor to THC. This gives you the option to use the oil in its raw, non-psychoactive form or to decarboxylate it at home for full psychoactive potency.

Option 1: Raw (Non-Psychoactive)

• Use the oil as-is, without heating it. This preserves the THCa in its acidic form, which is non-psychoactive and may provide anti-inflammatory and neuroprotective benefits.
• Ideal for daytime use, work, driving, or any situation where you need to stay clear-headed.

Option 2: Decarboxylated (Psychoactive)

• To decarboxylate the oil, preheat your oven to 260°F (125°C).
• Transfer the desired amount of oil to an oven-safe glass container (e.g., a small glass dish or ramekin).
• Place the container in the oven and heat for 45 to 60 minutes. This converts the THCa into delta-9 THC, giving the oil psychoactive potency comparable to traditional RSO.
• Let the oil cool before using it. You can store the decarboxylated oil in the refrigerator for up to two weeks.
• Ideal for nighttime use, sleep support, or situations where you want the full therapeutic benefits of THC.

Step 5: Store the Oil Properly

To preserve the potency and freshness of your RSO Sublingual Oil, store it in a cool, dark place away from direct sunlight and heat. The refrigerator is an ideal storage location, but the oil can also be stored at room temperature if kept in a dark, cool environment.

How to Use the RSO Vape Cartridge

Step 1: Attach the Cartridge to a Compatible Battery

The RSO Vape Cartridge is compatible with any standard 510-thread vape battery. To attach the cartridge, simply screw it onto the battery until it is securely in place.

Step 2: Start with a Small Inhalation

As with the sublingual oil, it’s important to start low and go slow when using the vape cartridge. Take a small inhalation (1 to 2 seconds) and wait 1 to 2 minutes to feel the effects. If you don’t feel the desired relief after this time, you can take another small inhalation, but be sure to wait at least 5 minutes between puffs to avoid overconsumption.

Step 3: Adjust Your Dose as Needed

The effects of the vape cartridge are felt almost immediately (1 to 2 minutes), making it easy to titrate your dose. Here are some general guidelines for adjusting your dose:

• For mild symptoms (e.g., occasional anxiety or minor pain): Start with 1 to 2 small inhalations and wait 5 to 10 minutes before taking more.
• For moderate symptoms (e.g., chronic pain or insomnia): Start with 2 to 3 inhalations and adjust as needed.
• For severe symptoms (e.g., chemotherapy-related nausea or PTSD): Start with 3 to 5 inhalations and work with a healthcare provider to find the right dose for your needs.

Step 4: Store the Cartridge Properly

To preserve the potency and freshness of your RSO Vape Cartridge, store it in a cool, dark place away from direct sunlight and heat. Avoid exposing the cartridge to extreme temperatures, as this can degrade the cannabinoids and terpenes.

Condition-Specific Usage Contexts

While our RSO products are not intended to diagnose, treat, cure, or prevent any disease, we understand that many Weakley County residents are using them to manage specific health conditions. Below, we’ll provide some general guidance on how to use our products for common conditions, along with important safety considerations.

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in this document and by OilWell’s formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence context: Delta-8 THC antiemetic evidence, delta-9 THC nausea and vomiting evidence, CBD anxiolytic buffering

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition

Sleep Support

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—the dosage level investigated in the 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance in published research
• Evidence context: CBN sleep evidence, cannabis and sleep review literature

Anxiety and Stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence, CBG pharmacology, limonene entourage-effect evidence

General Titration Principle

Start low, go slow. Begin with a low dose and assess the effects over a sufficient period before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Safety and Legal Considerations for Weakley County Residents

At OilWell Cannabis, we believe in responsible use. That’s why we’ve created this guide to help Weakley County residents understand the safety and legal considerations associated with our RSO products.

Safety Considerations

1. Start low and go slow: As with any cannabinoid product, it’s important to start with a low dose and gradually increase as needed. This is especially true for our RSO products, which are highly concentrated.

2. Avoid driving or operating machinery: Our RSO products contain psychoactive cannabinoids (delta-8 THC and delta-9 THC), which can impair your ability to drive or operate machinery. Do not use these products if you need to drive, work, or perform any task that requires alertness.

3. Consult your healthcare provider: If you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns, consult your healthcare provider before using our products. Cannabinoids can interact with certain medications, including blood thinners, antidepressants, and anti-anxiety drugs.

4. Keep out of reach of children and pets: Our RSO products are highly concentrated and should be kept out of reach of children and pets. Accidental ingestion can cause serious health effects, including intoxication, sedation, and respiratory depression.

5. Store products safely: Store our RSO products in a cool, dark place away from direct sunlight and heat. Keep them in their original packaging and out of reach of children and pets.

6. Be aware of potential side effects: Cannabinoids can cause side effects, including dry mouth, dizziness, fatigue, and changes in appetite. These side effects are usually mild and temporary, but they can be more severe at higher doses.

7. Avoid mixing with alcohol or other substances: Mixing cannabinoids with alcohol or other substances can increase the risk of side effects and impairment. Use our products responsibly and avoid combining them with other substances.

Legal Considerations

1. Age requirement: Our RSO products are intended for use by adults age 21 and older. It is illegal to sell or provide these products to anyone under the age of 21.

2. THC content compliance: Our RSO Sublingual Oil contains only 90 mg of delta-9 THC in the entire 30 mL bottle—well under the 0.3 percent threshold established by the 2018 Farm Bill. This makes the product legal under federal law and in most states.

3. THCa conversion: THCa converts to delta-9 THC when heated. While the product is legal at the point of sale, customers are responsible for understanding and complying with their local laws regarding the decarboxylation and use of THC-containing products.

4. State and local laws: Cannabis laws vary by state and locality. While our products are legal under federal law, some states and localities have additional restrictions or requirements. It is your responsibility to understand and comply with the laws in your jurisdiction.

5. International shipping: OilWell ships internationally to jurisdictions where hemp-derived products with less than 0.3 percent delta-9 THC are permitted. However, customers are responsible for verifying legality in their jurisdiction and accepting all customs and legal risk.

6. Drug testing: Our RSO products contain THC and other cannabinoids that may cause a positive result on a drug test. If you are subject to drug testing for employment, sports, or other purposes, be aware that using our products may result in a positive test.

7. Workplace policies: Some employers have policies prohibiting the use of cannabinoids, even if they are legal under state or federal law. Be aware of your employer’s policies and the potential consequences of using our products.

Important Legal Notice

Age requirements: 21+ for RSO products.

THC content compliance: All products contain less than 0.3% delta-9 THC; Farm Bill compliant; hemp-derived cannabinoids.

FDA disclaimers: Not evaluated by FDA; not intended to diagnose, treat, cure, or prevent any disease; consult healthcare provider before use; individual results may vary.

Safety warnings: May cause drowsiness or impairment; do not operate vehicles or machinery; consult physician if pregnant or nursing; keep out of reach of children.

Legal responsibility: Buyer responsibility to check local laws; company assumes no legal responsibility for customer’s use or decarboxylation decisions; void where prohibited by law.

Why OilWell’s RSO Is Different: A Message for Weakley County

In Weakley County, we value honesty, hard work, and community. We believe in products that are made with integrity, backed by science, and designed to help—not exploit—those who use them. That’s why OilWell’s RSO is different.

We Honor the Tradition, but We Don’t Replicate the Risks

Rick Simpson’s story resonates with many of us in Weakley County. Like Simpson, we’ve seen loved ones suffer and conventional medicine fall short. We’ve felt the frustration of being told there’s nothing more that can be done. But we also recognize that Simpson’s methods were limited by the tools and knowledge available to him at the time.

Traditional RSO was crude, unstandardized, and produced using solvents that carry real safety risks. At OilWell, we’ve taken the core idea behind RSO—a powerful, full-spectrum cannabis extract—and evolved it into something safer, more precise, and more accessible.

Our RSO formulas are solvent-free, lab-tested, and standardized to ensure consistent potency and purity. We’ve replaced the single-strain, THC-dominant approach with a multi-cannabinoid formula that includes CBD, CBG, delta-8 THC, THCa, CBN, and CBC—each chosen for its unique therapeutic potential. We’ve added live terpenes to enhance the experience and potentially contribute to the entourage effect. And we’ve given you control over whether the product is psychoactive or not, so you can use it in a way that fits your lifestyle.

We Believe in Transparency

In Weakley County, we don’t like hidden agendas or fine print. We value straight talk and honest dealings. That’s why we publish our complete formulas—every cannabinoid, every milligram amount, every percentage—so you know exactly what you’re getting.

We also believe in open-source access. If you can’t afford our products, you can see our formulas, source the ingredients, and make your own version. This is our way of honoring Rick Simpson’s original ethos: cannabis medicine should be accessible to everyone who needs it.

We’re Rooted in Real Stories

OilWell Cannabis wasn’t built in a boardroom. It was built in the real world, through real struggles and real triumphs.

It started with Bentley, a dog who was given up for dead but got up and walked because of cannabinoid medicine. It grew through Colin’s own battle with PTSD and benzodiazepine addiction, which he overcame using the same knowledge he used to save Bentley. And it continues through the stories of veterans, cancer patients, chronic pain sufferers, and everyday people in Weakley County and beyond who have found relief with our products.

These aren’t marketing stories. They’re real lives, real suffering, and real hope. And they’re the reason we do what we do.

We’re Here for Weakley County

Weakley County is our community, and we’re committed to serving it with the same integrity and care that we bring to every aspect of our business. Whether you’re in Dresden, Martin, Greenfield, or any of the small towns and rural areas that make up our county, we’re here to provide you with honest education, high-quality products, and exceptional service.

Our products are available for nationwide and international shipping, so you can access them no matter where you are. And if you’re in Houston, we offer same-day delivery to make it even easier to get the relief you need.

We Believe in the Power of Cannabis

At OilWell Cannabis, we believe that cannabis is one of the most powerful and versatile plants on Earth. It has the potential to alleviate suffering, improve quality of life, and offer hope when other treatments fail. But we also believe that with that power comes responsibility.

That’s why we’re committed to evidence-based education, responsible use, and products that are safe, effective, and transparent. We don’t make wild claims or promise miracles. We provide the best possible version of the information so you can decide for yourself whether our products are right for you.

A Final Word

If you’re reading this, you’re likely searching for something—relief from pain, better sleep, a way to manage anxiety, or hope in the face of a serious diagnosis. We understand that search, and we’re here to help.

Our RSO products are designed to bring the healing potential of cannabis to Weakley County in a way that’s legal, safe, and tailored to your needs. Whether you choose to use our products or make your own from our open-source formulas, we hope this guide has given you the information you need to make an informed decision.

Thank you for trusting us with your health and well-being. We’re honored to be part of your journey.

For more information or to place an order, visit OilWell Cannabis or call us at (832) 416-2816.

References

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq